Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Clinical Trials for Akesobio
Explore 8 clinical trials worldwide
Search
Showing 1-8 of 8 trials
Active filters:
Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruiting
Sponsor: Akesobio
Clinical Trials (8)
NCT07208773
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
PHASE1/PHASE2
Not yet recruiting
260 participants
Started: Oct 31, 2025 · Completed: Dec 31, 2027
3 conditions
2 sponsors
1 location
NCT06959550
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
PHASE2
Recruiting
90 participants
Started: Jul 28, 2025 · Completed: Jul 1, 2030
1 condition
3 sponsors
1 location
NCT06936644
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
PHASE2
Not yet recruiting
39 participants
Started: Apr 30, 2025 · Completed: Mar 30, 2028
1 condition
3 sponsors
0 locations
NCT06789848
Ligufalimab and Cadonilimab in Advanced Liver Cancers
PHASE2
Recruiting
64 participants
Started: Feb 18, 2025 · Completed: May 31, 2030
3 conditions
3 sponsors
1 location
NCT06491472
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
PHASE2
Recruiting
36 participants
Started: Jul 15, 2024 · Completed: Jul 15, 2027
1 condition
2 sponsors
1 location
NCT06416930
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
PHASE2
Not yet recruiting
59 participants
Started: Jun 20, 2024 · Completed: Jun 20, 2029
1 condition
2 sponsors
0 locations
NCT06187961
Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma
PHASE2
Recruiting
36 participants
Started: Dec 7, 2023 · Completed: Jun 30, 2027
1 condition
2 sponsors
1 location
NCT05021120
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
EARLY_PHASE1
Active, not recruiting
66 participants
Started: Oct 12, 2021 · Completed: May 27, 2025
1 condition
1 sponsor
5 locations